Beit Jala Pharmaceutical Company Achieves Record Profits in the First Half of 2025 Exceeding $2 Million

SadaNews Economy - Financial data released by Beit Jala Pharmaceutical Company for the first half of 2025 showed a significant improvement in performance with a growth rate exceeding 105%, according to financial analyst Dr. Samah Al-Attout. This is largely attributed to a substantial improvement in sales with a growth rate of nearly 42%. Domestic sales saw a significant increase of 30%, while international sales grew noticeably by 69%. An important factor showcasing the efficiency of management in handling costs is the profit margin, which rose to 43% from 31% during the same period in 2024. The company is trading at a market price of 2.80 dinars per share, with a book value based on first half data reaching 2.49 dinars per share. The company is trading at an excellent price-to-earnings ratio of 6.3 times, which is highly attractive for investment, and this can be attributed to a significant improvement in profitability recently due to rising export sales and improved profit margins. The company achieved a positive net operating cash flow of nearly $5 million during the first half of 2025.